| Title: |
How to Manage a Patient with Ocular Metastases? |
| Authors: |
Thariat, Juliette; Boudin, Laurys; Loria, Olivier; Nguyen, Anh-Minh; Kodjikian, Laurent; Mathis, Thibaud |
| Contributors: |
Laboratoire de physique corpusculaire de Caen (LPCC); Université de Caen Normandie (UNICAEN); Normandie Université (NU)-Normandie Université (NU)-École Nationale Supérieure d'Ingénieurs de Caen (ENSICAEN); Normandie Université (NU)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Centre National de la Recherche Scientifique (CNRS); Hôpital d'Instruction des Armées Sainte Anne; Service de Santé des Armées; Hôpital de la Croix-Rousse CHU - HCL; Hospices Civils de Lyon (HCL); Matériaux, ingénierie et science Villeurbanne (MATEIS); Université Claude Bernard Lyon 1 (UCBL); Université de Lyon-Université de Lyon-Institut National des Sciences Appliquées de Lyon (INSA Lyon); Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Centre National de la Recherche Scientifique (CNRS) |
| Source: |
Biomedicines ; https://hal.science/hal-03920563 ; Biomedicines, 2022, 10 (12), pp.3044. ⟨10.3390/biomedicines10123044⟩ |
| Publisher Information: |
CCSD |
| Publication Year: |
2022 |
| Collection: |
HAL Lyon 1 (University Claude Bernard Lyon 1) |
| Subject Terms: |
plaque brachytherapy; choroidal metastasis; ocular tumor; proton therapy; radiotherapy; [SDV.CAN]Life Sciences [q-bio]/Cancer; [SDV.MHEP.OS]Life Sciences [q-bio]/Human health and pathology/Sensory Organs |
| Description: |
International audience ; Ocular metastases are the most frequent ocular malignant tumors; their prevalence is estimated around 5–10% and is even higher in patients with breast or lung cancer. They represent various clinical situations, but they share the same hierarchical multidisciplinary therapeutic challenge with respect to the way systemic and local therapies should be selected in combination or sequentially in the personalized medical history of a patient. The challenges include tumor control, eye preservation, and the minimization of iatrogenic damage to sensitive tissues surrounding the tumor in order to preserve vision. These aims should further contribute to maintaining quality of life in patients with metastases. Many patients with choroidal metastases have systemic molecular treatment for their primary tumor. However, secondary resistance to systemic treatment is common and may ultimately be associated with cancer relapse, even after an initial response. Therefore, it makes sense to propose local treatment concomitantly or after systemic therapy to provide a more sustainable response. The aim of this review is to present current therapeutic strategies in ocular metastases and discuss how to tailor the treatment to a specific patient. |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| Relation: |
INSPIRE: 2619948 |
| DOI: |
10.3390/biomedicines10123044 |
| Availability: |
https://hal.science/hal-03920563; https://hal.science/hal-03920563v1/document; https://hal.science/hal-03920563v1/file/biomedicines-10-03044.pdf; https://doi.org/10.3390/biomedicines10123044 |
| Rights: |
https://creativecommons.org/licenses/by/4.0/ ; info:eu-repo/semantics/OpenAccess |
| Accession Number: |
edsbas.2D5AC0AD |
| Database: |
BASE |